Contribution of gene polymorphisms in the renin-angiotensin system to macroangiopathy in patients with diabetic nephropathy.

The renin-angiotensin system is important in the control of hemodynamic status and pathogenesis of macrovascular disease, which is a major cause of morbidity and mortality in patients with type 2 diabetes with nephropathy. Serum angiotensin-converting enzyme (ACE) and angiotensinogen (Atg) levels are related to their respective gene polymorphisms. Seventy patients with type 2 diabetes with overt nephropathy (serum creatinine >/= 1.5 mg/dL) were studied. Serum ACE activity was measured by the spectrophotometric method. ACE deletion/insertion (D/I) and Atg M235T genotypes were determined by polymerase chain reaction. Patients with and without macroangiopathy were compared. Those with macroangiopathy had increased ACE activity (median, 60.9 U/L; range, 37.9 to 100 U/L versus without macroangiopathy, 47.9 U/L; range, 11.2 to 84.5 U/L; P = 0.01) and prevalence of ACE DD/DI genotypes (DD/DI:II: with macroangiopathy, 61%:39% versus without macroangiopathy, 34%:66%; P = 0.03). Multivariate analysis using age; sex; duration of diabetes; glycemic, blood pressure, and lipid level control; serum creatinine level; and presence of the ACE D allele showed that presence of the D allele (P = 0.03; odds ratio, 1.8; confidence interval, 1.1 to 3.1) and serum creatinine level (P = 0.0007) were independent risk factors for macroangiopathy. Association of the D allele became insignificant after serum ACE activity was included in the analysis in which only serum ACE activity (P = 0.004) and serum creatinine level (P = 0.01) were independent risk factors. Neither Atg M235T nor its synergistic effect with the ACE D allele showed an association with macroangiopathy. In conclusion, the ACE D allele is associated with macroangiopathy in Chinese patients with type 2 diabetes with nephropathy. The association is dependent on its effect on serum ACE activity, which is an independent risk factor for the development of macroangiopathy.

[1]  J. Chan,et al.  Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. , 2000, Kidney international.

[2]  G. Remuzzi,et al.  ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. , 2000, Kidney international.

[3]  W. R. Lee,et al.  Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[4]  J. Chan,et al.  Lack of association of angiotensin-converting enzyme (DD/II) and angiotensinogen M235T gene polymorphism with renal function among Chinese patients with type II diabetes. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  O. Aras,et al.  Carotid intima-media thickness and ACE-gene polymorphism in hemodialysis patients. , 1999, Journal of nephrology.

[6]  G Chatellier,et al.  Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. , 1997, The Journal of clinical investigation.

[7]  I. Kubota,et al.  Association of ACE gene polymorphisms with coronary artery disease in a northern area of Japan. , 1995, Japanese heart journal.

[8]  J. Stricker,et al.  ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. , 1998, Atherosclerosis.

[9]  L. Tiret,et al.  Plasma Level and Gene Polymorphism of Angiotensin‐Converting Enzyme in Relation to Myocardial Infarction , 1994, Circulation.

[10]  Y. Ko,et al.  Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese , 1997, Human Genetics.

[11]  L. Duntas,et al.  Serum angiotensin-converting enzyme activity and active renin plasma concentrations in insulin-dependent diabetes mellitus. , 1992, Diabetes research and clinical practice.

[12]  H. Schunkert,et al.  Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. , 1997, Circulation.

[13]  M. Margaglione,et al.  Polymorphism of the Angiotensin-Converting Enzyme Gene in End-Stage Renal Failure Patients , 2000, Nephron.

[14]  C. Price,et al.  A Continuous Monitoring Spectrophotometric Method for the Measurement of Angiotensin-Converting Enzyme in Human Serum , 1985, Annals of clinical biochemistry.

[15]  J. Chan,et al.  Angiotensinogen T235 and ACE Insertion/Deletion Polymorphisms Associated With Albuminuria in Chinese Type 2 Diabetic Patients , 1998, Diabetes Care.

[16]  T. Shoji,et al.  Effect of Polymorphism of Apolipoprotein E and Angiotensin-Converting Enzyme Genes on Arterial Wall Thickness , 1997, Diabetes.

[17]  A. Manatunga,et al.  The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. , 1995, The Journal of clinical investigation.

[18]  D. Campbell,et al.  Angiotensin-converting enzyme determination in plasma during therapy with converting enzyme inhibitor: two methods compared. , 1991, Clinical chemistry.

[19]  F. Gejyo,et al.  Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1. , 1998, Kidney international.

[20]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[21]  T. Isbir,et al.  Association Between Angiotensin‐Converting Enzyme Gene Polymorphism and Coronary Artery Disease , 1999, IUBMB life.

[22]  E. Silverstein,et al.  Increased serum angiotensin-converting enzyme in chronic renal disease. , 1984, Nephron.

[23]  P. Li,et al.  Importance of dialysis adequacy in mortality and morbidity of chinese CAPD patients. , 2000, Kidney international.

[24]  J. Sulkes,et al.  Increased serum angiotensin converting enzyme activity in type T insulin—dependent diabetes mellitus: its relation to metabolic control and diabetic complications , 1994, European journal of clinical investigation.

[25]  A. Morris,et al.  DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. , 1999, Hypertension.

[26]  A. Barnett,et al.  Angiotensin‐Converting Enzyme (ACE): Relationship to Insulin‐dependent Diabetes and Microangiopathy , 1986, Diabetic medicine : a journal of the British Diabetic Association.

[27]  F. Cambien,et al.  Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R Kreutz,et al.  A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. , 1995, The New England journal of medicine.

[29]  M. Verani,et al.  Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. , 1997, Journal of the American College of Cardiology.

[30]  T. Lehtimäki,et al.  Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years. , 1998, Metabolism: clinical and experimental.

[31]  T. Ogihara,et al.  Angiotensin I-Converting Enzyme Gene Polymorphism Is Associated With Myocardial Infarction, but Not With Retinopathy or Nephropathy, in NIDDM , 1995, Diabetes Care.

[32]  J. Chan,et al.  Clinical and biochemical characteristics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: relationships with insulin requirement. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  P. Talmud,et al.  Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. , 1998, Diabetes.

[34]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[35]  W. Knowler,et al.  Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. , 1998, Metabolism: clinical and experimental.

[36]  P. Touboul,et al.  Plasma angiotensin-converting enzyme activity and carotid wall thickening. , 1994, Circulation.

[37]  H. Haring,et al.  Evaluation of the Insertion/Deletion ACE Gene Polymorphism as a Risk Factor for Carotid Artery Intima-Media Thickening and Hypertension in Young Type 1 Diabetic Patients , 1998, Diabetes Care.